Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more
Rxsight Inc (RXST) - Net Assets
Latest net assets as of September 2025: $275.97 Million USD
Based on the latest financial reports, Rxsight Inc (RXST) has net assets worth $275.97 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($308.53 Million) and total liabilities ($32.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $275.97 Million |
| % of Total Assets | 89.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 52.74 |
Rxsight Inc - Net Assets Trend (2019–2024)
This chart illustrates how Rxsight Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rxsight Inc (2019–2024)
The table below shows the annual net assets of Rxsight Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $281.24 Million | +75.38% |
| 2023-12-31 | $160.36 Million | +78.37% |
| 2022-12-31 | $89.90 Million | -34.97% |
| 2021-12-31 | $138.24 Million | +146.46% |
| 2020-12-31 | $-297.53 Million | +2.32% |
| 2019-12-31 | $-304.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rxsight Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20224000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.00K | 0.01% |
| Other Comprehensive Income | $166.00K | 0.06% |
| Other Components | $903.13 Million | 321.13% |
| Total Equity | $281.24 Million | 100.00% |
Rxsight Inc Competitors by Market Cap
The table below lists competitors of Rxsight Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhenhai PetroChem Engineering
SHG:603637
|
$277.87 Million |
|
Cooper Energy Ltd
AU:COE
|
$277.90 Million |
|
Compagnie Financière Tradition SA
PINK:CFNCF
|
$277.93 Million |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
$277.99 Million |
|
Byggmax Group AB
ST:BMAX
|
$277.67 Million |
|
Acco Brands Corporation
NYSE:ACCO
|
$277.61 Million |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
$277.51 Million |
|
Chongqing Sulian Plastic Co. Ltd. A
SHE:301397
|
$277.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rxsight Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 160,362,000 to 281,238,000, a change of 120,876,000 (75.4%).
- Net loss of 27,455,000 reduced equity.
- New share issuances of 128,916,000 increased equity.
- Other comprehensive income increased equity by 171,000.
- Other factors increased equity by 19,244,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.45 Million | -9.76% |
| Share Issuances | $128.92 Million | +45.84% |
| Other Comprehensive Income | $171.00K | +0.06% |
| Other Changes | $19.24 Million | +6.84% |
| Total Change | $- | 75.38% |
Book Value vs Market Value Analysis
This analysis compares Rxsight Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-15.97 | $7.56 | x |
| 2020-12-31 | $-15.60 | $7.56 | x |
| 2021-12-31 | $5.05 | $7.56 | x |
| 2022-12-31 | $3.25 | $7.56 | x |
| 2023-12-31 | $4.65 | $7.56 | x |
| 2024-12-31 | $7.24 | $7.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rxsight Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.62%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.13x
- Recent ROE (-9.76%) is above the historical average (-24.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 5632.31% | 0.02x | 0.00x | $156.68 Million |
| 2020 | 0.00% | 187.87% | 0.15x | 0.00x | $57.33 Million |
| 2021 | -35.22% | -215.50% | 0.12x | 1.39x | $-62.51 Million |
| 2022 | -74.25% | -136.22% | 0.33x | 1.67x | $-75.75 Million |
| 2023 | -30.31% | -54.57% | 0.49x | 1.14x | $-64.64 Million |
| 2024 | -9.76% | -19.62% | 0.44x | 1.13x | $-55.58 Million |
Industry Comparison
This section compares Rxsight Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rxsight Inc (RXST) | $275.97 Million | 0.00% | 0.12x | $277.68 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |